Sudhan S. George
Sudhan S. George has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Jyothsna Volisha Cardoza
Krupanidhi college of Physiotherapy
2 shared publicationsVijay Pratap Singh
Kasturba Medical College, Manipal Academy of Higher Education
2 shared publicationsZeeshan Ali
Krupanidhi college of Physiotherapy
2 shared publicationsAlessandro Contini
Università degli Studi di Milano, Sezione di Chimica Generale e Organica “A. Marchesini
1 shared publication- Bidita Khandelwal
Sikkim Manipal Institute of Medical Sciences, Sikkim Manipal University
1 shared publication - Janhavi Sandeep Khandekar
Department of Physiotherapy, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India
1 shared publication
Latest Publications
- Open Access
- 30 October 2023
- Published by Springer Nature in Research Square
Alkaloids and Quinolones as potential MtbTopI inhibitors: An in-silico discovery using ADME studies and molecular dynamics simulation
Mycobacterium tuberculosis (M.tb), the causative agent of Tuberculosis, threats human lives more than any other infectious diseases worldwide. Despite of various developed drugs against M.tb, lack of an efficient therapeutic has led to continuous formulation of new drugs against the disease. The bacteria's specific adaptations to achieve drug resistance operate as a defensive mechanism, thereby making the development of anti-mycobacterial drugs particularly complicated. Therefore, targeting new receptors in the bacteria to develop a potential drug is recommended. In this study, a pool of alkaloid and quinolone compounds have been screened against the M.tb Topoisomerase I receptor. The prime function of MtbTopI in mycobacterium is to maintain DNA topology and regulate the torsional stress during DNA replication. Targeting MtbTopI can not only disrupt DNA structure, but also lead to restricted growth and ultimately death of the pathogen. A total of 257 alkaloids and 1515 quinolones were screened in silico against the receptor to find compounds able to inhibit the growth of Mycobacterium tuberculosis. One alkaloid and two quinolones were eventually found as potential inhibitors of MtbTopI.
- 30 October 2023
- Published by Springer Nature in Research Square
Open AccessAlkaloids and Quinolones as potential MtbTopI inhibitors: An in-silico discovery using ADME studies and molecular dynamics simulation
Mycobacterium tuberculosis (M.tb), the causative agent of Tuberculosis, threats human lives more than any other infectious diseases worldwide. Despite of various developed drugs against M.tb, lack of an efficient therapeutic has led to continuous formulation of new drugs against the disease. The bacteria's specific adaptations to achieve drug resistance operate as a defensive mechanism, thereby making the development of anti-mycobacterial drugs particularly complicated. Therefore, targeting new receptors in the bacteria to develop a potential drug is recommended. In this study, a pool of alkaloid and quinolone compounds have been screened against the M.tb Topoisomerase I receptor. The prime function of MtbTopI in mycobacterium is to maintain DNA topology and regulate the torsional stress during DNA replication. Targeting MtbTopI can not only disrupt DNA structure, but also lead to restricted growth and ultimately death of the pathogen. A total of 257 alkaloids and 1515 quinolones were screened in silico against the receptor to find compounds able to inhibit the growth of Mycobacterium tuberculosis. One alkaloid and two quinolones were eventually found as potential inhibitors of MtbTopI.
- 22 July 2023
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 196 (4) , 2137-2160
A Multi-epitope Vaccine Candidate Against Bolivian Hemorrhagic fever Caused by Machupo Virus
Bolivian hemorrhagic fever (BHF) caused by Machupo virus (MACV) is a New World arenavirus having a reported mortality rate of 25–35%. The BHF starts with fever, followed by headache, and nausea which rapidly progresses to severe hemorrhagic phase within 7 days of disease onset. One of the key promoters for MACV viral entry into the cell followed by viral propagation is performed by the viral glycoprotein (GPC). GPC is post-transcriptionally cleaved into GP1, GP2 and a signal peptide. These proteins all take part in the viral infection in host body. Therefore, GPC protein is an ideal target for developing therapeutics against MACV infection. In this study, GPC protein was considered to design a multi-epitope, multivalent vaccine containing antigenic and immunogenic CTL and HTL epitopes. Different structural validations and physicochemical properties were analysed to validate the vaccine. Docking and molecular dynamics simulations were conducted to understand the interactions of the vaccine with various immune receptors. Finally, the vaccine was codon optimised in silico and along with which immune simulation studies was performed in order to evaluate the vaccine’s effectiveness in triggering an efficacious immune response against MACV.
- 22 July 2023
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 196 (4) , 2137-2160
A Multi-epitope Vaccine Candidate Against Bolivian Hemorrhagic fever Caused by Machupo Virus
Bolivian hemorrhagic fever (BHF) caused by Machupo virus (MACV) is a New World arenavirus having a reported mortality rate of 25–35%. The BHF starts with fever, followed by headache, and nausea which rapidly progresses to severe hemorrhagic phase within 7 days of disease onset. One of the key promoters for MACV viral entry into the cell followed by viral propagation is performed by the viral glycoprotein (GPC). GPC is post-transcriptionally cleaved into GP1, GP2 and a signal peptide. These proteins all take part in the viral infection in host body. Therefore, GPC protein is an ideal target for developing therapeutics against MACV infection. In this study, GPC protein was considered to design a multi-epitope, multivalent vaccine containing antigenic and immunogenic CTL and HTL epitopes. Different structural validations and physicochemical properties were analysed to validate the vaccine. Docking and molecular dynamics simulations were conducted to understand the interactions of the vaccine with various immune receptors. Finally, the vaccine was codon optimised in silico and along with which immune simulation studies was performed in order to evaluate the vaccine’s effectiveness in triggering an efficacious immune response against MACV.
- 6 February 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (22) , 13348-13367
Computational design of candidate multi-epitope vaccine against SARS-CoV-2 targeting structural (S and N) and non-structural (NSP3 and NSP12) proteins
The COVID-19 pandemic caused by SARS-CoV-2 virus has created a global damage and has exposed the vulnerable side of scientific research towards novel diseases. The intensity of the pandemic is huge, with mortality rates of more than 6 million people worldwide in a span of 2 years. Considering the gravity of the situation, scientists all across the world are continuously attempting to create successful therapeutic solutions to combat the virus. Various vaccination strategies are being devised to ensure effective immunization against SARS-CoV-2 infection. SARS-CoV-2 spreads very rapidly, and the infection rate is remarkably high than other respiratory tract viruses. The viral entry and recognition of the host cell is facilitated by S protein of the virus. N protein along with NSP3 is majorly responsible for viral genome assembly and NSP12 performs polymerase activity for RNA synthesis. In this study, we have designed a multi-epitope, chimeric vaccine considering the two structural (S and N protein) and two non-structural proteins (NSP3 and NSP12) of SARS-CoV-2 virus. The aim is to induce immune response by generating antibodies against these proteins to target the viral entry and viral replication in the host cell. In this study, computational tools were used, and the reliability of the vaccine was verified using molecular docking, molecular dynamics simulation and immune simulation studies in silico. These studies demonstrate that the vaccine designed shows steady interaction with Toll like receptors with good stability and will be effective in inducing a strong and specific immune response in the body. Communicated by Ramaswamy H. Sarma
- 6 February 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (22) , 13348-13367
Computational design of candidate multi-epitope vaccine against SARS-CoV-2 targeting structural (S and N) and non-structural (NSP3 and NSP12) proteins
The COVID-19 pandemic caused by SARS-CoV-2 virus has created a global damage and has exposed the vulnerable side of scientific research towards novel diseases. The intensity of the pandemic is huge, with mortality rates of more than 6 million people worldwide in a span of 2 years. Considering the gravity of the situation, scientists all across the world are continuously attempting to create successful therapeutic solutions to combat the virus. Various vaccination strategies are being devised to ensure effective immunization against SARS-CoV-2 infection. SARS-CoV-2 spreads very rapidly, and the infection rate is remarkably high than other respiratory tract viruses. The viral entry and recognition of the host cell is facilitated by S protein of the virus. N protein along with NSP3 is majorly responsible for viral genome assembly and NSP12 performs polymerase activity for RNA synthesis. In this study, we have designed a multi-epitope, chimeric vaccine considering the two structural (S and N protein) and two non-structural proteins (NSP3 and NSP12) of SARS-CoV-2 virus. The aim is to induce immune response by generating antibodies against these proteins to target the viral entry and viral replication in the host cell. In this study, computational tools were used, and the reliability of the vaccine was verified using molecular docking, molecular dynamics simulation and immune simulation studies in silico. These studies demonstrate that the vaccine designed shows steady interaction with Toll like receptors with good stability and will be effective in inducing a strong and specific immune response in the body. Communicated by Ramaswamy H. Sarma
- Open Access
- 13 September 2021
- Published by Hindawi Limited in The Scientific World Journal
- Vol. 2021, 1-10
Effect of Yoga on Blood Pressure in Prehypertension: A Systematic Review and Meta-Analysis
Introduction. Prehypertension is a precursor for developing hypertension and is a risk factor for cardiovascular diseases. Yoga therapy may have a role in lowering the blood pressures in prehypertension and hypertension. This systematic review aims to synthesize the available literature for the same. Methodology. Databases such as PubMed, Embase, Scopus, and Web of Science were searched for randomised control trials only in the time duration of 20102021. The main outcome of interest was systolic and diastolic blood pressures. Articles were screened based on the inclusion criteria, and 8 articles were recruited for the review. Meta-analysis was done for suitable articles. RevMan 5.4 by Cochrane was used for meta-analysis and forest plot construction. Risk of bias was determined using the Downs and Black checklist by three independent authors. Results. The meta-analysis of the articles favoured yoga intervention over the control intervention. Yoga therapy had significantly reduced the systolic pressure (0.62 standard mean difference, at IV fixed 95 CI: 0.83, 0.41) and diastolic pressure (0.81 standard mean difference, at IV random 95 CI: 1.39, 0.22). Secondary outcome measures studied were heart rate, weight, BMI, waist circumference, and lipid profile. The main protocol of yoga therapy included postures, breathing exercises, and different meditation techniques. A significant reduction in secondary outcomes was observed, except for HDL values in lipid profile which showed a gradual increase in yoga group in comparison with alternative therapy. Conclusion. Yoga therapy has shown to be significant in the reduction of systolic and diastolic pressure in prehypertensive population. Supporting evidence lacks in providing a proper structured dosage of yoga asanas and breathing techniques. Considering the existing literature and evidence, Yoga therapy can be used and recommended in prehypertensive population and can be beneficial in reducing the chances of developing hypertension or cardiovascular diseases.
- 13 September 2021
- Published by Hindawi Limited in The Scientific World Journal
- Vol. 2021, 1-10
Open AccessEffect of Yoga on Blood Pressure in Prehypertension: A Systematic Review and Meta-Analysis
Introduction. Prehypertension is a precursor for developing hypertension and is a risk factor for cardiovascular diseases. Yoga therapy may have a role in lowering the blood pressures in prehypertension and hypertension. This systematic review aims to synthesize the available literature for the same. Methodology. Databases such as PubMed, Embase, Scopus, and Web of Science were searched for randomised control trials only in the time duration of 20102021. The main outcome of interest was systolic and diastolic blood pressures. Articles were screened based on the inclusion criteria, and 8 articles were recruited for the review. Meta-analysis was done for suitable articles. RevMan 5.4 by Cochrane was used for meta-analysis and forest plot construction. Risk of bias was determined using the Downs and Black checklist by three independent authors. Results. The meta-analysis of the articles favoured yoga intervention over the control intervention. Yoga therapy had significantly reduced the systolic pressure (0.62 standard mean difference, at IV fixed 95 CI: 0.83, 0.41) and diastolic pressure (0.81 standard mean difference, at IV random 95 CI: 1.39, 0.22). Secondary outcome measures studied were heart rate, weight, BMI, waist circumference, and lipid profile. The main protocol of yoga therapy included postures, breathing exercises, and different meditation techniques. A significant reduction in secondary outcomes was observed, except for HDL values in lipid profile which showed a gradual increase in yoga group in comparison with alternative therapy. Conclusion. Yoga therapy has shown to be significant in the reduction of systolic and diastolic pressure in prehypertensive population. Supporting evidence lacks in providing a proper structured dosage of yoga asanas and breathing techniques. Considering the existing literature and evidence, Yoga therapy can be used and recommended in prehypertensive population and can be beneficial in reducing the chances of developing hypertension or cardiovascular diseases.